PI3Kδ

June 14, 2019

ME-401 Experimental Compound Reduces Tumor Burden in Follicular Lymphoma, Phase 1 Trial Shows

News

MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among ... Read more

May 25, 2016May 25, 2016

Idelalisib for Indolent Non-Hodgkin Lymphoma a Viable Option, Review Finds

News

In a comprehensive review of idelalisib (Zydelig) treatment for patients with indolent non-Hodgkin lymphoma, Hofstra University’s Jacqueline C Barrientos concluded that the drug is a promising option in patients who have already been ... Read more

April 19, 2016April 19, 2016

Clinical Trial of Chi-Med’s B-Cell Lymphoma Drug Is Launched

News

Hutchison China MediTech Limited, generally called Chi-Med, recently announced the initiation of its first-in-human Phase 1 clinical trial of HMPL-689, a drug the company aims to evaluate in B-cell malignancies. The ... Read more